October 18, 1993; and is a continuation-in-part of 07/991,997 filed December 17, 1992, now

abandoned; which is a continuation-in-part of 07/963,308 filed October 16, 1992, now

abandoned.

> *The amendments to the specification presented above incorporate changes as indicated*
> *by the marked-up versions below.*

 This application is a continuation of application number 08/893,274, filed on July 15,

1997, now U.S. Patent No. 5,968,821.; which is a continuation of 08/306,511 filed September

14, 1994 9/14/94, now U.S. Patent No. 5,962,316; which is a continuation-in-part of 08/248,812

filed May 25, 1994 5/25/94, now U.S. Patent No. 5,889,169; which is a continuation-in-part of

08/154,915 filed November 18, 1993 11/18/93; which is a National Stage Application of claims

priority to PCT/US93/09945, filed October 18, 1993 10/18/93.; and is a continuation-in-part of

07/991,997 filed December 17, 1992 12/17/92, now abandoned (abandoned); which is a

continuation-in-part of 07/963,308 filed October 16, 1992 10/16/92, now abandoned.

In the claims:

 Please cancel claims 96 and 97 without prejudice. Please amend claims 91, 92, 94, 95,

98, 103, 104, 106, 108, and 111. For the convenience of the Examiner, all claims being

examined, whether or not amended, are presented below.

91. (Amended) An isolated antibody specifically reactive with a 16 kD protein that co-

precipitates with CDK4 from cell lysates of SV40-transformed WI38 cells in the presence of an

anti-CDK4 antibody, wherein the molecular weight of the 16 kD protein is identified by

polyacrylamide gel electrophoresis (PAGE) under denaturing conditions.

92. (Amended) An isolated antibody specifically immunoreactive with a 16 kD protein that

co-precipitates with CDK4 from cell lysates of SV40-transformed WI38 cells in the presence of

an anti-CDK4 antibody, wherein the molecular weight of the 16 kD protein is identified by

PAGE under denaturing conditions.

93. (Reiterated) The antibody of claim 92, wherein the antibody is a monoclonal antibody.